New York, NY -- (SBWIRE) -- 01/06/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: E Commerce China Dangdang Inc (ADR) (NYSE:DANG), Rockwell Medical Inc (NASDAQ:RMTI), BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX), Gafisa SA (ADR) (NYSE:GFA)
E Commerce China Dangdang Inc (ADR) (NYSE:DANG) showed a volume of 1.65 million shares by the end of last trade whereas the average volume of the stock remained 1.60million shares. The stock opened the session at $9.85 but then moved to $9.42. At that price, the stock showed a negative performance of -3.38%. E-Commerce China Dangdang Inc. (Dangdang) is a holding company. It is a business-to-consumer (B2C), e-commerce Company in the People’s Republic of China. As of September 30, 2010, it offered approximately 590,000 book titles on its Website, including more than 570,000 Chinese language titles. The Company also offers other media products and selected general merchandise categories on its Website, including beauty and personal care products,
Will DANG Get Buyers Even After The Recent Rally? Find Out Here
Rockwell Medical Inc (NASDAQ:RMTI) opened the session at $10.43and closed the session at $9.88. The stock showed a negative performance of -5.27% in previous trading session. Traded with volume of 1.61 million shares in the prior session and the average volume of the stock remained 1.18 million shares. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD).
Has RMTI Found The Bottom And Ready To Gain Momentum? Find Out Here
BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) opened the session at $7.95 and closed the session at $8.46. The stock showed a positive performance of 7.09% in previous trading session. Traded with volume of 1.58 million shares in the prior session and the average volume of the stock remained 947,543.00 shares. The beta of the stock remained 3.03. BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. BioCryst designs, optimizes and develops drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on therapeutic areas. Peramivir is its product, which is a neuraminidase inhibitor for the treatment of patients with influenza. The Company has two purine nucleoside phosphorylase (PNP) inhibitors that are in development,
Why Should Investors Buy BCRX After The Recent Gain? Just Go Here and Find Out
Gafisa SA (ADR) (NYSE:GFA) the stock advanced 6.23% and finished the session at $3.07. Traded with volume of 1.58 million shares in the prior session and the average volume of the stock remained 1.55 million shares. The beta of the stock remained 2.56. Gafisa SA is a Brazil-based company engaged in the homebuilding and real estate operations. The Company is involved in the promotion, administration, purchase, sale and trade of real estate properties; provision of financing services to real estate customers; construction and provision of civil engineering services, and development and implementation of marketing strategies related to its own or third party real estate projects.
Will GFA Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)